Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 19/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.75 |
| ▸ | LMNA | P02545 | 1/20 | 0.75 |
| ▸ | MAPT | P10636 | 1/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.75 |
| ▸ | ATM | Q13315 | 1/20 | 0.75 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.75 |
| ▸ | CNR2 | P34972 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31282223 | 0.90 | CNR1 (0.82) | CNR1MEN1LMNAMAPTKMT2A | |
| SCHEMBL31282617 | 0.90 | CNR1 (0.80) | CNR1MEN1LMNAMAPTKMT2A | |
| SCHEMBL17548442 | 0.88 | CNR1 (1.00) | CNR1MEN1LMNAMAPTKMT2A | |
| SCHEMBL31282971 | 0.88 | CNR1 (1.00) | CNR1MEN1LMNAMAPTKMT2A | |
| SCHEMBL31282735 | 0.87 | CNR1 (0.76) | CNR1MEN1LMNAMAPTKMT2A | |
| SCHEMBL31282334 | 0.87 | CNR1 (0.76) | CNR1MEN1LMNAMAPTKMT2A | |
| SCHEMBL31282892 | 0.86 | CNR1 (0.76) | CNR1MEN1LMNAMAPTKMT2A | |
| SCHEMBL31282198 | 0.86 | CNR1 (0.76) | CNR1MEN1LMNAMAPTKMT2A | |
| SCHEMBL31282119 | 0.86 | CNR1 (0.74) | CNR1MEN1LMNAMAPTKMT2A | |
| SCHEMBL31282574 | 0.86 | CNR1 (0.74) | CNR1MEN1LMNAMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118681-A1 | CANNABINOID TYPE 1 RECEPTOR MODULATORS | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2018-05-03 | — | — | US | disclosed |
| WO-2016029310-A1 | CANNABINOID TYPE 1 RECEPTOR MODULATORS | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2016-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118681-A1 | CANNABINOID TYPE 1 RECEPTOR MODULATORS | CNR1, CNR2, GPR18 | CNR1 1/4885MEN1 3818/4885LMNA 3469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.